Breast health

Tamoxifen for Prevention: Who Might Consider It

Save

Tamoxifen is a risk-reducing (chemoprevention) pill for women at clearly elevated breast cancer risk. In the NSABP P-1 trial it lowered invasive breast cancer by about 49%, with benefit lasting beyond the treatment years. It also raises the risk of uterine cancer and blood clots, so candidacy is decided individually with a clinician.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What is tamoxifen for breast cancer prevention?

Tamoxifen is a pill that lowers the odds of developing breast cancer in women at higher-than-average risk. As a selective estrogen receptor modulator (SERM), it blocks estrogen from stimulating breast tissue, where many breast cancers are fueled by estrogen. Long used to treat breast cancer, it is also approved to prevent it, an approach called chemoprevention or risk reduction. In the National Surgical Adjuvant Breast and Bowel Project P-1 trial, tamoxifen reduced invasive breast cancer by about 49% compared with placebo 1. The benefit is largest for estrogen-receptor-positive cancers, the most common type, and it does not treat cancers that have already formed. Staying current with mammogram screening by age remains part of the plan even for women taking it 2.

Who might be offered risk-reducing tamoxifen?

Tamoxifen for prevention is aimed at women whose estimated breast cancer risk is clearly above average, not the general population. Eligibility in the P-1 trial required a predicted risk over 5 years of about 1.67% or higher, calculated from age, family history, past breast biopsies, and reproductive history 1. According to breast cancer risk-assessment guidance, which recommends validated risk models, clinicians decide who benefits enough to justify the tradeoffs 3. Women with an inherited risk, such as a BRCA change or a strong family history, sit at the higher end of that range 4. Reviewing the screenings women need by age can help frame where formal risk assessment fits. Prevention is one option among several, including closer surveillance.

How much does it lower risk, and for how long?

The protection tamoxifen offers is substantial and outlasts the treatment itself. In the P-1 trial, invasive breast cancer fell by about 49% over the study, and follow-up shows the risk reduction continues for years after the usual course of about 5 years ends 1. Put in absolute terms, that means a meaningful drop in cases among high-risk women, though the exact benefit depends on how high a given woman's starting risk is. Tamoxifen mainly lowers estrogen-receptor-positive breast cancer and has little effect on receptor-negative disease. Because the benefit persists, a finite course can pay off well beyond the years a woman actually takes the pill. Screening and self-awareness, including knowing when a breast lump is worth worrying about, still matter throughout.

What are the tradeoffs and side effects?

Tamoxifen carries real risks that must be weighed against its benefit. In prevention trials it increased the risk of uterine (endometrial) cancer and of blood clots in the legs and lungs, and it commonly causes hot-flash-like symptoms 1. Because a preventive course is typically taken for about 5 years, those risks accrue over that time, though most serious events stay uncommon in absolute terms 1. Tamoxifen can be used in both premenopausal and postmenopausal women, whereas raloxifene, a related SERM, is an alternative studied only in postmenopausal women 5. Managing overlapping menopausal complaints, such as hot flashes and night sweats, is part of tolerating the medicine. The right answer balances a woman's breast cancer risk against her clot and uterine risks.

When to discuss tamoxifen for prevention with a clinician

Deciding on preventive tamoxifen is a personalized calculation best made with a clinician who can estimate your risk. A strong family history, a prior high-risk breast biopsy, a known genetic change, or a formal risk estimate above the threshold are reasons to seek clinician review of whether risk-reducing therapy fits 3. On the medicine, new leg swelling or pain, chest pain, breathlessness, or abnormal vaginal bleeding are reasons to seek prompt medical care, because they can signal a clot or a uterine problem. A specialist such as a gynecologist, breast clinician, or genetic counselor typically guides the choice. Gale can help you gather your family history and questions before that appointment.

Common questions

In the NSABP P-1 prevention trial, tamoxifen lowered invasive breast cancer by about 49% in high-risk women, and the protection continued for years after the usual five-year course. It mainly reduces estrogen-receptor-positive cancers, the most common type.

It is generally offered to women whose estimated five-year breast cancer risk is about 1.67% or higher, based on age, family history, past biopsies, and reproductive factors. Inherited risk, such as a BRCA change, raises that estimate. A clinician calculates risk using a validated model.

The notable risks are a higher chance of uterine cancer and blood clots, along with hot-flash-like symptoms. Most serious events are uncommon in absolute terms, but they are the reason tamoxifen is offered only when the expected benefit clearly outweighs them.

A typical preventive course runs about five years. Because the risk reduction lasts well beyond the years of active treatment, a finite course can keep lowering risk afterward. The exact plan is individualized with the prescribing clinician.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Tamoxifen: symptoms that need attention

  • —Sudden swelling, pain, warmth, or redness in one leg, or chest pain and shortness of breath, can signal a blood clot and is a reason to seek urgent medical care.
  • —Any new abnormal vaginal bleeding or spotting, especially after menopause, is a reason to seek clinician review because it can indicate a uterine problem.
  • —A new breast lump, one-sided breast change, or nipple change is a reason to seek clinician review.
  • —New vision changes or severe, persistent pelvic pain is a reason to seek clinician review.

Signs of a blood clot, such as sudden swelling or pain in one leg, chest pain, or shortness of breath, need same-day emergency care; call 911 or go to the nearest emergency room.

This article is general health education, not medical advice. Whether risk-reducing tamoxifen is right for you depends on your personal breast cancer risk and health history, and should be decided with a gynecologist, breast specialist, or genetic counselor.

References

  1. 1.Fisher B, Costantino JP, Wickerham DL, et al. / National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. doi:10.1093/jnci/90.18.1371 ✓The NSABP P-1 prevention trial: tamoxifen reduced invasive breast cancer by about 49% in high-risk women, with eligibility set at a 5-year predicted risk of about 1.67% or higher, and increased endometrial cancer and clot risk.
  2. 2.National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025). Breast Cancer Screening. National Cancer Institute (NCI), NIH. link ✓Breast cancer screening ages and rationale; supports the point that mammography screening remains part of care for women taking risk-reducing medication.
  3. 3.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓Breast cancer risk assessment using validated models to identify women who benefit from risk-reducing strategies; supports the candidacy and shared-decision framing.
  4. 4.National Cancer Institute (2024). BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute (NCI), NIH. link ✓BRCA changes and strong family history raise breast cancer risk; supports the point that inherited risk places women at the higher end of the eligibility range.
  5. 5.Vogel VG, Costantino JP, Wickerham DL, et al. / NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. doi:10.1001/jama.295.23.joc60074 ✓The STAR trial compared tamoxifen with raloxifene in postmenopausal women; supports the point that raloxifene is an alternative studied only after menopause.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library